Cargando…

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification

Detalles Bibliográficos
Autores principales:	Xiao, Teresa L., Ezenwa, Ekene, Ruiz de Luzuriaga, Arlene, Hoffman, Mark D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841365/ https://www.ncbi.nlm.nih.gov/pubmed/36654767 http://dx.doi.org/10.1016/j.jdcr.2022.11.028

Ejemplares similares

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
por: Yao, Jiayin, et al.
Publicado: (2023)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review
por: Do, Phinga, et al.
Publicado: (2021)

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
por: Saman, Sadik, et al.
Publicado: (2019)

Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
por: Scribano, Maria Lia, et al.
Publicado: (2022)

Successful Treatment of Refractory Autoimmune Enteropathy With Ustekinumab
por: Scheid, Johannes F., et al.
Publicado: (2021)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
por: Aguiar Zdovc, Jurij, et al.
Publicado: (2021)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Ustekinumab-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn's Disease
por: Jordan, Ariel, et al.
Publicado: (2022)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab
por: Axiaris, Georgios, et al.
Publicado: (2023)

Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease
por: Miklusiak, Klaudia, et al.
Publicado: (2023)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease †
por: Bertani, Lorenzo, et al.
Publicado: (2023)

Successful use of ustekinumab therapy in refractory severe atopic dermatitis
por: Shroff, Anjali, et al.
Publicado: (2014)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020)

A case report of disseminated verrucosis secondary to ustekinumab in a patient with Crohn’s disease
por: Svoboda, Steven A, et al.
Publicado: (2021)

Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients
por: Doherty, Matthew K., et al.
Publicado: (2018)

Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease
por: He, Manrong, et al.
Publicado: (2021)

Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature
por: Matsumoto, Satohiro, et al.
Publicado: (2020)

Pustular Rash in Crohn's Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
por: Barahimi, Mitra, et al.
Publicado: (2021)

Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease
por: Srinivasan, Ashish, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gb4pi0vu8895scl58vr8d3cudm